减少心力衰竭患者的盐摄入:一项系统综述
该研究系统检索多个数据库,纳入9项随机临床试验、共479例成人心力衰竭患者,评估减少膳食盐摄入对心血管死亡、全因死亡、不良事件及住院、纽约心脏协会功能分级等结局的影响。结果显示,没有研究提供主要结局的充分数据;2项门诊研究报告限盐未改善纽约心脏协会功能分级,另2项研究报告显著改善。作者认为门诊患者临床改善证据有限,住院患者证据不确定,支持或反驳现行指南的稳健高质量证据匮乏,建议开展设计良好、样本量充足的研究。
要点
- 该系统综述纳入9项随机临床试验、共479例成人心力衰竭患者,没有一项研究纳入超过100例参与者。
- 没有一项纳入研究提供心血管死亡、全因死亡或不良事件等主要结局的充分数据。
- 2项门诊研究报告限盐未改善纽约心脏协会功能分级,而另2项研究报告纽约心脏协会功能分级显著改善。
- 门诊患者减少膳食盐摄入的临床改善证据有限,住院患者证据不确定。
- 作者认为,支持或反驳现行限盐指南的稳健高质量证据匮乏,需要设计良好、样本量充足的研究。
适用人群与场景
- 成人住院或门诊心力衰竭患者。
研究设计与关键结果
- 研究类型为系统综述,检索Cochrane Central Register of Controlled Trials、MEDLINE、Embase和CINAHL等数据库,最终纳入9项随机临床试验、共479例独特参与者,没有一项研究纳入超过100例参与者。
- 9项研究的偏倚风险不一,没有一项研究提供主要结局(心血管相关死亡、全因死亡及卒中、心肌梗死等不良事件)的充分数据。
- 次要结局中,2项门诊研究报告限制盐摄入未改善纽约心脏协会功能分级,另2项研究报告纽约心脏协会功能分级显著改善。
- 作者结论认为,门诊患者减少膳食盐摄入的临床改善证据有限,住院患者证据不确定,支持或反驳现行指南的稳健高质量证据匮乏。
- 作者建议开展设计良好、样本量充足的研究以减少该干预应用的不确定性。
证据类型、等级与局限
- 证据类型为系统综述,方案注册号PROSPERO CRD42015019504。
- 局限:纳入研究中没有一项超过100例参与者。
- 局限:9项研究的偏倚风险不一。
- 局限:没有一项研究提供主要结局的充分数据。
- 局限:门诊患者临床改善证据有限,住院患者证据不确定。
- 局限:支持或反驳现行指南的稳健高质量证据匮乏。
对床旁实践的改变
- 作者认为,目前支持或反驳现行限盐指南的稳健高质量证据匮乏,门诊患者临床改善证据有限,住院患者证据不确定。
- 作者建议开展设计良好、样本量充足的研究以减少该干预应用的不确定性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recent estimates suggest that more than 26 million people worldwide have heart failure. The syndrome is associated with major symptoms, significantly increased mortality, and extensive use of health care. Evidence-based treatments influence all these outcomes in a proportion of patients with heart failure. Current management also often includes advice to reduce dietary salt intake, although the benefits are uncertain.
OBJECTIVE: To systematically review randomized clinical trials of reduced dietary salt in adult inpatients or outpatients with heart failure.
EVIDENCE REVIEW: Several bibliographic databases were systematically searched, including the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and CINAHL. The methodologic quality of the studies was evaluated, and data associated with primary outcomes of interest (cardiovascular-associated mortality, all-cause mortality, and adverse events, such as stroke and myocardial infarction) and secondary outcomes (hospitalization, length of inpatient stay, change in New York Heart Association [NYHA] functional class, adherence to dietary low-salt intake, and changes in blood pressure) were extracted.
FINDINGS: Of 2655 retrieved references, 9 studies involving 479 unique participants were included in the analysis. None of the studies included more than 100 participants. The risks of bias in the 9 studies were variable. None of the included studies provided sufficient data on the primary outcomes of interest. For the secondary outcomes of interest, 2 outpatient-based studies reported that NYHA functional class was not improved by restriction of salt intake, whereas 2 studies reported significant improvements in NYHA functional class.
CONCLUSIONS AND RELEVANCE: Limited evidence of clinical improvement was available among outpatients who reduced dietary salt intake, and evidence was inconclusive for inpatients. Overall, a paucity of robust high-quality evidence to support or refute current guidance was available. This review suggests that well-designed, adequately powered studies are needed to reduce uncertainty about the use of this intervention.
PROTOCOL REGISTRATION: PROSPERO Identifier: CRD42015019504.
参考来源
- Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced Salt Intake for Heart Failure: A Systematic Review. JAMA Intern Med. 2018. PMID: 30398532. doi:10.1001/jamainternmed.2018.4673
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。